A Phase III, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome?Positive Acute Lymphoblastic Leukemia Ph+ ALL

Brief Summary

Type:
Leukemias

Study Type:
Treatment

Phase:
III

ClinicalTrials.gov Identifier:
NCT03589326

Study #:
STUDY00144847

Start Date:
Sep 29, 2020

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03589326

View Complete Trial Details & Eligibility at ClinicalTrials.gov